---
title: "Lysergide (DT120) in Generalized anxiety disorder: Product comparison"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Product comparison. Topics: Effect sizes of DT120 placed beside approved GAD treatments: company presentation, Effect sizes of approved GAD drug classes: meta-analysis of 21 placebo-controlled trials cited by the company, HAM-A differences from placebo for approved and off-label GAD drugs: network meta-analysis of 89 trials, DT120 HAM-A differences from placebo in the phase 3 trials, and 8 further topics. 12 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/product-comparison"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Effect sizes of DT120 placed beside approved GAD treatments: company presentation

| Treatment and time point | Effect size |
| --- | --- |
| DT120, phase 2b MMED008, Week 12 | “0.81” |
| DT120 ODT, Voyage, Week 12 | “0.81” |
| DT120 ODT, Panorama, Week 12 | “0.64” |
| DT120, phase 2b MMED008, Week 4 | “0.88” |
| DT120 ODT, Voyage, Week 4 | “0.99” |
| DT120 ODT, Panorama, Week 4 | “0.96” |
| Benzodiazepines | “0.38” |
| SRIs | “0.36” |
| Buspirone | “0.17” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “DT120 effect size consistently larger than GAD standard of care”
> “The information presented in this slide is derived from multiple clinical trials, each conducted under distinct protocols and settings. As such, these data may not be directly comparable due to the lack of a head-to-head comparison.”
> “Buspirone and benzodiazepines are approved for anxiety disorders which include GAD”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.14-2"></a>

### Effect sizes of approved GAD drug classes: meta-analysis of 21 placebo-controlled trials cited by the company

> “We conducted an effect size (ES) analysis of 21 double-blind placebo-controlled trials of medications treating DSM-III-R, DSM-IV or ICD-10 GAD using HAM-A change in score from baseline or endpoint score as the main efficacy measure.”
> “comparing all drugs versus placebo, the ES was 0.39. Mean ESs, excluding children, were PGB: 0.50, AH: 0.45, SNRI: 0.42, BZ: 0.38, SSRI: 0.36, AZA: 0.17 and CAM: -0.31.”

Source: [Hidalgo et al. (2007)](https://pubmed.ncbi.nlm.nih.gov/17984162/)

<a id="topic-2.1.2.14-3"></a>

### HAM-A differences from placebo for approved and off-label GAD drugs: network meta-analysis of 89 trials

> “This analysis is based on 89 trials, which included 25 441 patients randomly assigned to 22 different active drugs or placebo.”
> “Duloxetine (MD -3·13, 95% credible interval [CrI] -4·13 to -2·13), pregabalin (MD -2·79, 95% CrI -3·69 to -1·91), venlafaxine (MD -2·69, 95% CrI -3·50 to -1·89), and escitalopram (MD -2·45, 95% CrI -3·27 to -1·63) were more efficacious than placebo with relatively good acceptability.”
> “Quetiapine (MD -3·60 95% CrI -4·83 to -2·39) had the largest effect on HAM-A but it was poorly tolerated (odds ratio 1·44, 95% CrI 1·16-1·80) when compared with placebo.”

Source: [Slee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30712879/)

<a id="topic-2.1.2.14-4"></a>

### DT120 HAM-A differences from placebo in the phase 3 trials

> “The Least Squares (LS) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -9.8 compared with -4.7 for participants who received placebo, an LS mean difference of -5.1 points (p<0.0001), corresponding to a standardized effect size of d=0.64.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “The Least Squares (“LS”) mean change from baseline in HAM-A total score at Week 12 in participants who received DT120 ODT 100 µg was -11.6 compared with -6.2 for participants who received placebo, an LS mean difference of -5.4 points (p<0.0001), corresponding to a standardized effect size of d=0.81.”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.2.14-5"></a>

### FDA-approved pharmacotherapies for GAD in adults

> “Escitalopram has been approved by the FDA for the treatment of GAD in adults”
> “As an FDA-approved treatment for GAD in adults, immediate release paroxetine has been studied extensively and multiple studies support its efficacy in adults with GAD.”
> “In adults with GAD, venlafaxine (75–225 mg/day) effectively reduces anxiety symptoms [36–38] and was the first FDA-approved antidepressant for the treatment of GAD in this age group.”
> “Duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, is FDA-approved for the treatment of GAD, MDD, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain.”
> “Buspirone, a non-benzodiazepine anxiolytic and 5-HT1A receptor agonist, is approved for the treatment of GAD in adults”
> “As such, alprazolam is the only benzodiazepine to be formally approved by the FDA for the treatment of GAD.”

Source: [Strawn et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6340395/)

<a id="topic-2.1.2.14-6"></a>

### Most recent FDA approval of a new drug for GAD: differing company statements

> “Despite the significant personal and societal burden of GAD, there has been little innovation in the treatment of GAD in the past several decades, with the last new drug approval occurring in 2004.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

> “Few treatment options have shown robust activity in GAD, with the last new FDA approval occurring in 2007.”

Source: [MindMed end-of-phase 2 meeting announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/149/mindmed-announces-constructive-end-of-phase-2-meeting-with-u-s-fda-for-mm120-in-generalized-anxiety-disorder-gad)

<a id="topic-2.1.2.14-7"></a>

### Dosing paradigm: single administered dose compared with daily oral therapy

> “Single dose regimen is being studied in pivotal clinical trials with primary and secondary outcome measures through 12 weeks after administration.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “Patients with generalized anxiety disorder often work through two or three medications before finding one they can tolerate, and even then, daily dosing brings its own burden, sedation, weight change, sexual side effects, and for some classes of medications, real dependence risk,”
> “What stands out about DT120 ODT is that a single dose has the potential to hold a response for months without the patient managing a pill every day.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

> “Patients with GAD and MDD are typically treated with a variety of anxiolytic and antidepressant medications, including selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors and benzodiazepines.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.14-8"></a>

### Monitored-administration model: esketamine nasal spray under the SPRAVATO REMS

> “Risk for sedation, dissociation, and respiratory depression after administration. Monitor patients for at least two hours after administration.”
> “SPRAVATO is only available through a restricted program called the SPRAVATO REMS.”
> “Administer SPRAVATO intranasally under the supervision of a healthcare provider.”

Source: [Janssen SPRAVATO prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf)

<a id="topic-2.1.2.14-9"></a>

### Monitored-administration model: DT120 session length in the phase 3 trials

> “Participants were monitored for a minimum of 8 hours on dosing day and were assessed hourly beginning 5 hours after dosing on a structured end-of-session checklist (EoSC).”
> “The average time to meet EoSC criteria was 6.2 hours for participants receiving DT120 ODT 100 μg, with a median of 6.0 hours and 94% of participants meeting EoSC criteria by hour 8.”

Source: [Definium Therapeutics Panorama topline results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/251/definium-therapeutics-announces-positive-topline-results-from-phase-3-panorama-study-of-dt120-odt-in-generalized-anxiety-disorder)

<a id="topic-2.1.2.14-10"></a>

### Prescriber intent to administer DT120 compared with esketamine: company market research

| Response of high-priority GAD prescribers | DT120 ODT | Esketamine |
| --- | --- | --- |
| Prescribe and administer the treatment in own practice | “51%” | “26%” |
| Refer out (for DT120, the treatment; for esketamine, for esketamine) | “40%” | “61%” |
| Only discuss if a patient raises it (DT120), or refer out for evaluation without specifying esketamine | “9%” | “14%” |

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

> “GAD Target Validation Market Research, 2025. High-priority HCPs represent deciles 7-10 of GAD prescribers. In the conduct of market research, DT120 was blinded as “Treatment X” to respondents.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.14-11"></a>

### LSD compared with psilocybin: effect duration in healthy participants

| Effect | 15 mg psilocybin | 30 mg psilocybin | 100 µg LSD | 200 µg LSD |
| --- | --- | --- | --- | --- |
| Effect duration (h), mean ± SD | “5.6 ± 2.2” | “6.5 ± 2.4” | “9.3 ± 3.2” | “11 ± 3.7” |

Source: [Holze et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9018810/)

> “The doses of 100 and 200 µg LSD and 30 mg psilocybin produced comparable subjective effects.”
> “LSD at both doses had clearly longer effect durations than psilocybin.”
> “The elimination half-life values of LSD and psilocin were an average of ~4 h and 2.5 h, respectively.”

Source: [Holze et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9018810/)

<a id="topic-2.1.2.14-12"></a>

### Other psychedelic and serotonergic agents in development for GAD and depressive disorders, as listed by the company

> “A number of companies are developing product candidates with similar mechanisms to DT120 that are intended for the treatment of anxiety and depressive disorders, including AtaiBeckley Inc. (“AtaiBeckley”), Compass Pathways plc (“Compass”), GH Research (“GH Research”), Cybin, Inc. doing business as Helus Pharma (“Helus”), Johnson & Johnson (“J&J”), Otsuka Pharmaceutical Co. Ltd. (“Otsuka”) and others.”
> “Helus is currently evaluating HLP004 (a serotonin receptor agonist) in a Phase 2 trial for the treatment of GAD, with an anticipated topline data readout in the first quarter of 2026. In addition, Otsuka is currently conducting a Phase 2/3 clinical trial of ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1) agonist with 5-HT1A agonist activity, for the treatment of GAD and MDD.”
> “Intra-Cellular Therapies, now a part of J&J (“Intra-Cellular”), is currently developing multiple product candidates that are in various phases of development for the treatment of GAD and MDD, including CAPLYTA (lumateperone), which was approved by the FDA in November 2025 as an adjunctive treatment for adults with MDD, and ITI-1284 ODT-SL for GAD.”
> “Compass is developing COMP360 (a proprietary formulation of psilocybin) that is in Phase 3 clinical trials for the treatment of TRD in adults and is being studied in other psychiatric indications (anorexia nervosa and post-traumatic stress disorder).”
> “There are also many other public and private companies developing therapeutics from the psychedelic drug class at various stages of development, including certain short-acting psychedelic drugs.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.14-13"></a>

### Head-to-head clinical comparison of DT120 with an approved GAD treatment

No evidence found.

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
